Up to 144 New Stock Opportunities Make This Sector Ripe for Profits

There’s a sector of the market that doesn’t follow the same rules as the others. The gains folks take from this sector are indeed explosive. But to take these gains, you have to pinpoint unique catalysts that are difficult to uncover. Today we blow the lid off the industry and show you how you can find these catalysts easily. There’s a sector of the market that doesn’t follow the same rules as the others. The gains folks take from this sector are indeed explosive. But to take these gains, you have to pinpoint unique catalysts that are difficult to uncover. Today we blow the lid off the industry and show you how you can find these catalysts easily. [Energy and Capital logo] Up to 144 New Stock Opportunities Make This Sector Ripe for Profits [Sean McCloskey Photo] By [Sean McCloskey]( Written May 14, 2021 During my analyst coverage in 2018, I covered the biotech sector very closely. In doing so, I learned two very important things. The first is that the success of an individual medical technology (medtech) or biotechnology (biotech) company isn’t directly tied to the greater cyclical forces that often affect other stocks. The second thing I learned is that over the course of time, the medtech and biotech industries offer investors the most chances at triple-digit gains in any given month. This is because medtech and biotech stocks are catalyst-driven. Let me show you a few examples. A Sector That Is Always Ripe for Profits On April 5, 2018, I recommended a lesser-known biotech formerly named Seattle Genetics, now named Seagen Inc. (NASDAQ: SGEN), at a price of $53.38. By the end of the year, the stock had nearly doubled in value after rising over $80 per share. [SGEN 2018 Chart] The catalyst back in 2018 was an FDA approval on its Adcetris therapy for the treatment of Hodgkin's lymphoma. More specifically, this therapy represented the first FDA-approved regimen for frontline treatment of Stage 3 and 4 Hodgkin's lymphoma in over 40 years. That’s significant. The chart above covers the following five months as the market got wind of the drug’s efficacy and effectiveness. Even despite a massive sell-off as the herd took profits late in 2018, shares today are near new all-time highs at $139. It’s important to know that these opportunities are not random events. This New Battery Could Dethrone Tesla [twa electric glass finger]( A brand-new type of battery is about to flood the markets and dethrone Tesla forever. This battery is up to 10 times more powerful than Tesla’s famed lithium-ion battery and is absolutely tiny — roughly the size of a drop of water. This is a rare second chance to take part in a world-shifting innovation. [Click here to see the details.]( On May 23, 2018, I recommended Merck & Co. (NYSE: MRK) at $58.45. By late December 2019, shares were trading just shy of $90. [MRK 2018-2019 Chart] The reason for the pop? In 2018, MRK was close to releasing a new cancer drug called Keytruda. Trial data was very promising, which was very important because Keytruda had the potential to treat numerous different forms of cancer. That catalyst powered MRK shares to some nice gains and quick profits for those who took my advice at the time. And there’s more. Just a month later, on June 27, 2018, I suggested my followers take a swing on Inspire Medical Systems (NYSE: INSP) at a price of $36.32. The company had just IPO’d a few months prior, and the catalyst for big gains was that it had the only FDA-approved internal sleep apnea device on the market. The product eliminates the need for clunky masks and is monitored via handheld remote. When activated during sleep, the device opens the user's airways, allowing for a full night's sleep. The product was revolutionary and only just recently approved — the perfect catalyst for gains. Today, INSP trades around $180, representing an open gain of over 399% so far. I could go on with the gains folks like you can score in the biotech and medtech sectors, such as Amgen Inc. (NASDAQ: AMGN) at 46%, Ocular Therapeutix (NASDAQ: OCUL) at 92%, or even the Ark Genomic Revolution ETF (ARKG), which is led by future tech investment guru Cathy Wood and, despite pullback in all Ark ETFs recently, is still up over 146% over the past two years as of this past Tuesday. The point is if you know how to spot the catalyst before it ignites a surge, you can make a pretty profit in a relatively short time frame. Some of these time frames can be extremely short, and if you have stakes in the even more explosive opportunities, you can make some serious cash. Millions of These Modules Will Be Deployed Across the U.S. Power Grid Soon Investors who understand why this tiny module is about to revolutionize the power grid stand to multiply their money. Power outages cost the U.S. economy upward of $150 billion each year due to a number of reasons, from faulty cables that cause disastrous wildfires to hostile cyberattacks aimed at the grid, threatening the lives of millions of Americans. But this brand-new technology will put an end to all of this. Republicans and Democrats alike are behind this massive project... And you can get in on this $2.9 trillion opportunity before Wall Street catches on. [Click here to find out (for free) what this is all about.]( Take for instance some recent wins from my colleague and market analyst Keith Kohl: - A two-week 225% payday on Intra-Cellular Therapies - A one-week gain of 60% on Durect Corporation - A 25% winner on Allied Healthcare Products in just five days Plus many more. One of Your Best Trading Opportunities of the Year It isn't easy to capture these fast-moving paydays. The information about these catalysts isn’t readily available. However, in a unique one-time event, you can join Keith for a special Catalyst Calendar summit where he will show you where you can learn about these opportunities and and how to cash in on these flash gains. By registering for this [special one-time event](, you can take part in one of the biggest trading opportunities of the year. It takes place on May 20 at 3 p.m. EST. If you’ve been looking for a way to up your trading game, this online summit is your answer. You’ll learn how you could take advantage of up to 144 opportunities each year that could produce results like: - A 43% winner on Marinus Pharmaceuticals - A 59% gain on Dova Pharmaceuticals - A 75% windfall on Clearside Biomedical All in relatively short amounts of time. Add up all these wins, and you’ll have yourself one heck of a trading year. But to learn how to lock in these gains week in and week out, you must join Keith at his special Catalyst Calendar summit on May 20 at 3 p.m. EST. Sign up [right here](, right now. Reservations are limited and filling up fast. We’ll talk again soon. To your wealth, Sean McCloskey Editor, Energy and Capital [[follow basic]@TheRL_McCloskey on Twitter]( After spending 10 years in the consumer tech reporting and educational publishing industries, Sean has since redevoted himself to one of his original passions: identifying and cashing in on the most lucrative opportunities the market has to offer. As the former managing editor of multiple investment newsletters, he's covered virtually every sector of the market, ranging from energy and tech to gold and cannabis. Over the years, Sean has offered his followers the chance to score numerous triple-digit gains, and today he continues his mission to deliver followers the best chance to score big wins on Wall Street and beyond as an editor for Energy and Capital. Browse Our Archives [What They're Not Telling You About the Colonial Pipeline Cyberattack]( [How to Trade the FDA Approval Game]( [Investing in the End of Pandemics]( [Bold Prediction: Bitcoin to $125,000]( [Warren Buffett, Robinhood, and the New Paradigm for Creating Wealth in the 21st Century]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Energy and Capital, please add newsletter@energyandcapital.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. [Energy and Capital](, Copyright © 2021, [Angel Publishing LLC](. All rights reserved. 3 E Read Street, Baltimore, MD 21202. The content of this site may not be redistributed without the express written consent of Angel Publishing. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and Energy and Capital as well as a link to www.energyandcapital.com. Your privacy is important to us -- we will never rent or sell your e-mail or personal information. Please read our [Privacy Policy](. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. [Energy and Capital]( does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. The publisher, editors and consultants of Angel Publishing may actively trade in the investments discussed in this publication. They may have substantial positions in the securities recommended and may increase or decrease such positions without notice. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. ---------------------------------------------------------------